Abstract

Patients with ovarian cancer are typically diagnosed at an advanced stage, resulting in poor prognosis since there are currently no effective early-detection screening tests for women at average-risk for ovarian cancer. Here, we investigated the effects of MT-6, a derivative of moscatilin, in ovarian cancer cells. Our investigation showed that MT-6 inhibited the proliferation and viability of ovarian cancer cells with submicromolar IC50 values. MT-6-treated SKOV3 cells showed significant cell cycle arrest at G2/M phase, followed by an increase in the proportion of cells in a sub-G1 phase. In addition, MT-6 induced a concentration-dependent increase in mitotic markers, mitotic kinases, cell cycle regulators of G2/M transition, and apoptosis-related markers in ovarian cancer cells. MT-6 treatment also induced mitochondrial membrane potential loss, JNK activation, and DR5 expression. Cotreatment of cells with the JNK inhibitor SP600125 considerably attenuated MT-6-induced apoptosis, mitochondria membrane potential loss, DR5 upregulation, and suppression of cell viability. MT-6 also inhibited tumor growth in an SKOV3 xenograft model without significant body weight loss. Together, our findings suggest that MT-6 is a potent anticancer agent with tumor-suppressive activity in vitro and in vivo that could be further investigated for ovarian cancer therapy in the future.

Original languageEnglish
Article number46149
JournalScientific Reports
Volume7
DOIs
Publication statusPublished - Apr 7 2017

Fingerprint

Ovarian Neoplasms
Apoptosis
Mitochondrial Membrane Potential
G2 Phase
G1 Phase
Cell Cycle Checkpoints
Heterografts
Cell Division
Antineoplastic Agents
Membrane Potentials
Inhibitory Concentration 50
Weight Loss
Neoplasms
Cell Survival
Cell Cycle
Mitochondria
Phosphotransferases
Up-Regulation
Body Weight
Therapeutics

ASJC Scopus subject areas

  • General

Cite this

The apoptotic mechanisms of MT-6, a mitotic arrest inducer, in human ovarian cancer cells. / Chen, Mei Chuan; Kuo, Yi Chiu; Hsu, Chia Ming; Chen, Yi Lin; Shen, Chien Chang; Teng, Che Ming; Pan, Shiow Lin.

In: Scientific Reports, Vol. 7, 46149, 07.04.2017.

Research output: Contribution to journalArticle

Chen, Mei Chuan ; Kuo, Yi Chiu ; Hsu, Chia Ming ; Chen, Yi Lin ; Shen, Chien Chang ; Teng, Che Ming ; Pan, Shiow Lin. / The apoptotic mechanisms of MT-6, a mitotic arrest inducer, in human ovarian cancer cells. In: Scientific Reports. 2017 ; Vol. 7.
@article{516a0816066044418a8f8d837aae487d,
title = "The apoptotic mechanisms of MT-6, a mitotic arrest inducer, in human ovarian cancer cells",
abstract = "Patients with ovarian cancer are typically diagnosed at an advanced stage, resulting in poor prognosis since there are currently no effective early-detection screening tests for women at average-risk for ovarian cancer. Here, we investigated the effects of MT-6, a derivative of moscatilin, in ovarian cancer cells. Our investigation showed that MT-6 inhibited the proliferation and viability of ovarian cancer cells with submicromolar IC50 values. MT-6-treated SKOV3 cells showed significant cell cycle arrest at G2/M phase, followed by an increase in the proportion of cells in a sub-G1 phase. In addition, MT-6 induced a concentration-dependent increase in mitotic markers, mitotic kinases, cell cycle regulators of G2/M transition, and apoptosis-related markers in ovarian cancer cells. MT-6 treatment also induced mitochondrial membrane potential loss, JNK activation, and DR5 expression. Cotreatment of cells with the JNK inhibitor SP600125 considerably attenuated MT-6-induced apoptosis, mitochondria membrane potential loss, DR5 upregulation, and suppression of cell viability. MT-6 also inhibited tumor growth in an SKOV3 xenograft model without significant body weight loss. Together, our findings suggest that MT-6 is a potent anticancer agent with tumor-suppressive activity in vitro and in vivo that could be further investigated for ovarian cancer therapy in the future.",
author = "Chen, {Mei Chuan} and Kuo, {Yi Chiu} and Hsu, {Chia Ming} and Chen, {Yi Lin} and Shen, {Chien Chang} and Teng, {Che Ming} and Pan, {Shiow Lin}",
year = "2017",
month = "4",
day = "7",
doi = "10.1038/srep46149",
language = "English",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - The apoptotic mechanisms of MT-6, a mitotic arrest inducer, in human ovarian cancer cells

AU - Chen, Mei Chuan

AU - Kuo, Yi Chiu

AU - Hsu, Chia Ming

AU - Chen, Yi Lin

AU - Shen, Chien Chang

AU - Teng, Che Ming

AU - Pan, Shiow Lin

PY - 2017/4/7

Y1 - 2017/4/7

N2 - Patients with ovarian cancer are typically diagnosed at an advanced stage, resulting in poor prognosis since there are currently no effective early-detection screening tests for women at average-risk for ovarian cancer. Here, we investigated the effects of MT-6, a derivative of moscatilin, in ovarian cancer cells. Our investigation showed that MT-6 inhibited the proliferation and viability of ovarian cancer cells with submicromolar IC50 values. MT-6-treated SKOV3 cells showed significant cell cycle arrest at G2/M phase, followed by an increase in the proportion of cells in a sub-G1 phase. In addition, MT-6 induced a concentration-dependent increase in mitotic markers, mitotic kinases, cell cycle regulators of G2/M transition, and apoptosis-related markers in ovarian cancer cells. MT-6 treatment also induced mitochondrial membrane potential loss, JNK activation, and DR5 expression. Cotreatment of cells with the JNK inhibitor SP600125 considerably attenuated MT-6-induced apoptosis, mitochondria membrane potential loss, DR5 upregulation, and suppression of cell viability. MT-6 also inhibited tumor growth in an SKOV3 xenograft model without significant body weight loss. Together, our findings suggest that MT-6 is a potent anticancer agent with tumor-suppressive activity in vitro and in vivo that could be further investigated for ovarian cancer therapy in the future.

AB - Patients with ovarian cancer are typically diagnosed at an advanced stage, resulting in poor prognosis since there are currently no effective early-detection screening tests for women at average-risk for ovarian cancer. Here, we investigated the effects of MT-6, a derivative of moscatilin, in ovarian cancer cells. Our investigation showed that MT-6 inhibited the proliferation and viability of ovarian cancer cells with submicromolar IC50 values. MT-6-treated SKOV3 cells showed significant cell cycle arrest at G2/M phase, followed by an increase in the proportion of cells in a sub-G1 phase. In addition, MT-6 induced a concentration-dependent increase in mitotic markers, mitotic kinases, cell cycle regulators of G2/M transition, and apoptosis-related markers in ovarian cancer cells. MT-6 treatment also induced mitochondrial membrane potential loss, JNK activation, and DR5 expression. Cotreatment of cells with the JNK inhibitor SP600125 considerably attenuated MT-6-induced apoptosis, mitochondria membrane potential loss, DR5 upregulation, and suppression of cell viability. MT-6 also inhibited tumor growth in an SKOV3 xenograft model without significant body weight loss. Together, our findings suggest that MT-6 is a potent anticancer agent with tumor-suppressive activity in vitro and in vivo that could be further investigated for ovarian cancer therapy in the future.

UR - http://www.scopus.com/inward/record.url?scp=85017248448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017248448&partnerID=8YFLogxK

U2 - 10.1038/srep46149

DO - 10.1038/srep46149

M3 - Article

AN - SCOPUS:85017248448

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 46149

ER -